Moleculin says MIRACLE trial posts 37% interim CRc rate in venetoclax-failed AML patients

• Moleculin Biotech reported updated interim data from Part A of its pivotal MIRACLE trial in relapsed or refractory acute myeloid leukemia.
• Results have been disclosed now in a blinded analysis; comprehensive unblinded Part A results are expected in the December 2026 to February 2027 window.
• Patients who previously failed venetoclax showed remission outcomes broadly consistent with the overall study population.
• The company continued to report no signal of cardiac toxicity, supporting its differentiation from standard anthracyclines.
• Enrollment reached 74 of 90 patients; the final Part A treatment is expected in September 2026, a key step toward advancing the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-025167), on July 31, 2026, and is solely responsible for the information contained therein.